Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference

Rhea-AI Summary

Gracell Biotechnologies (NASDAQ: GRCL), a clinical-stage biopharmaceutical company, announced its participation in the B Riley Securities 2022 Virtual Oncology Conference, scheduled for January 27-28, 2022. The management team will present on January 27 from 2:30 PM to 3:30 PM Eastern Time, and will host virtual investor meetings on both event days. A webcast of the presentation will be accessible on the company's website, with a replay available for 90 days afterward. Gracell specializes in developing innovative cell therapies to effectively treat cancer.

SUZHOU, China and PALO ALTO, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the B Riley Securities 2022 Virtual Oncology Conference from January 27^th to 28^th.

The Gracell team is scheduled to have a presentation at 2:30pm - 3:30pm Eastern Time, January 27^th and will host virtual investor meetings at the conference on January 27^th and 28^th.

A webcast of the presentation will be available on the "Events and Presentations" page of the Investors section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit ir.gracellbio.com.

About Gracell 
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR, TruUCAR and SMART CART^TM technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact 
Marvin Tang 
marvin.tang@gracellbio.com

Investor contact 
Gracie Tong 
gracie.tong@gracellbio.com

 

FAQ

When is Gracell's presentation at the B Riley Securities 2022 Virtual Oncology Conference?

Gracell's presentation is scheduled for January 27, 2022, from 2:30 PM to 3:30 PM Eastern Time.

What dates will Gracell participate in the B Riley Securities 2022 Virtual Oncology Conference?

Gracell will participate in the conference on January 27 and 28, 2022.

Where can I watch the Gracell presentation from the oncology conference?

The presentation will be available on the 'Events and Presentations' page of Gracell's Investors section of their website.

How long will the replay of Gracell's conference presentation be available?

A replay of Gracell's presentation will be available for 90 days following the event.

What is the focus of Gracell Biotechnologies?

Gracell focuses on discovering and developing cell therapies for cancer treatment.